Future growth expectations in earnings/operating earnings/profits/EPS?

Expected ARPOB growth of 4-5% annually over next 2-3 years. Cluster-wise steady-state EBITDA margins targeted at 20%-25%. New hospitals (e.g., Bangalore units) expected to become EBITDA neutral within 12 months of commissioning. Losses from new units (Nashik, Thane) expected to neutralize by end of FY '26 or Q3, FY '27. Incremental bed capacities in various locations expected to ramp up over 4-5 years to about 70%-75% occupancy. Telangana cluster occupancy expected to rise from current ~50% to 65%-70%, potentially increasing margins. The company aims for overall earnings growth driven by expan

Any current/future new fundraising through debt or equity?

The transcript does not explicitly mention any current or planned new fundraising through debt or equity. Focus is on stabilizing and ramping up operations for newly commissioned hospitals before considering further expansions. Post stabilization of ongoing greenfield hospitals, the company plans to explore new greenfield projects primarily in Karnataka, Kerala, Maharashtra, Telangana, and Andhra Pradesh. No specific fundraise timeline or instruments (debt/equity) are disclosed in the available discussion.

Any current/future capex/capital investment/strategic investment?

The company is currently commissioning new hospital beds in multiple locations including Thane, Bangalore, Nashik, and Maharashtra cluster, with phased bed additions planned (e.g., starting with 50-100 beds, gradually increasing to full capacity over 3-4 years). Significant greenfield and brownfield expansions are ongoing, particularly in Telangana, Andhra Pradesh, Karnataka, Kerala, and Maharashtra. New facilities in Bangalore (800 beds) and Thane (300 beds) are being brought online, with anticipated EBITDA breakeven within 12 months of operation. Expansion includes adding specialties such as

Future growth expectations in sales/revenue/volumes?

Mature clusters like Telangana and Andhra Pradesh are expected to grow IP volumes at a moderate 5%-6% annually, with Telangana seeing acceleration from new hospital openings like Kondapur and Gachibowli expansions. New facilities in Bangalore, Thane, and Nashik are in ramp-up stages; Bangalore's hospitals aim to reach EBITDA breakeven by ~30%-40% occupancy within 12 months of commissioning. Maharashtra and other micro-markets (Karnataka, Kerala) show strong long-term growth potential with good traction from doctors and unmet demand in Tier 2/3 cities. Oncology and other specialty offerings are

Current/ Expected Orderbook/ Pending Orders?

The company is currently stabilizing greenfield hospitals commissioned in the current year and plans to start closing on new greenfield hospitals towards the end of the year. New greenfield hospital projects typically take 3-4 years to stabilize operations. Expansion focus remains on Karnataka, Kerala, Maharashtra, Telangana, and Andhra Pradesh. No explicit numeric order book or pending orders mentioned, but the company is actively exploring opportunities within existing clusters. Existing announced projects are expected to conclude commissioning by end of FY 2027. Post stabilization of curren

IN US

Sale is live|00:00:00left today

Krishna Institute of Medical Sciences LtdQ2 FY26Healthcare Services

Krishna Institute of Medical Sciences Ltd Q2 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹803P/E: 122.9Market Cap: ₹30.5K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

→Mature clusters like Telangana and Andhra Pradesh are expected to grow IP volumes at a moderate 5%-6% annually, with Telangana seeing acceleration from new hospital openings like Kondapur and Gachibowli expansions.
→New facilities in Bangalore, Thane, and Nashik are in ramp-up stages; Bangalore's hospitals aim to reach EBITDA breakeven by ~30%-40% occupancy within 12 months of commissioning.
→Maharashtra and other micro-markets (Karnataka, Kerala) show strong long-term growth potential with good traction from doctors and unmet demand in Tier 2/3 cities.
→Oncology and other specialty offerings are being expanded to improve case mix and ARPOB, especially in newer and Andhra clusters.
→ARPOB growth of around 4%-5% annually is expected overall, with higher ARPOB in new markets raising blended ARPOB to approximately INR 50,000–55,000 in the coming years.
→Capacity utilization and bed additions will drive volume increase, although new capacity commissioning will take 4-5 years to reach 70% occupancy levels.

Margin guidance

Category 3

→Expected ARPOB growth of 4-5% annually over next 2-3 years.
→Cluster-wise steady-state EBITDA margins targeted at 20%-25%.
→New hospitals (e.g., Bangalore units) expected to become EBITDA neutral within 12 months of commissioning.
→Losses from new units (Nashik, Thane) expected to neutralize by end of FY '26 or Q3, FY '27.
→Incremental bed capacities in various locations expected to ramp up over 4-5 years to about 70%-75% occupancy.
→Telangana cluster occupancy expected to rise from current ~50% to 65%-70%, potentially increasing margins.
→The company aims for overall earnings growth driven by expansion in Maharashtra, Karnataka, Kerala, and mature clusters like Telangana and Andhra.
→No specific consolidated EPS guidance provided, but current EPS showed 9.2% YoY degrowth, implying growth focus on operational ramp-up and margin improvement.

3 more insights locked — sign up free to unlock

Fundraise plans

→The transcript does not explicitly mention any current or planned new fundraising through debt or equity.
→Focus is on stabilizing and ramping up operations for newly commissioned hospitals before considering further expansions.
→Post stabilization of ongoing greenfield hospitals, the company plans to explore new greenfield projects primarily in Karnataka, Kerala, Maharashtra, Telangana, and Andhra Pradesh.
→No specific fundraise timeline or instruments (debt/equity) are disclosed in the available discussion.

Order book

→The company is currently stabilizing greenfield hospitals commissioned in the current year and plans to start closing on new greenfield hospitals towards the end of the year.
→New greenfield hospital projects typically take 3-4 years to stabilize operations.
→Expansion focus remains on Karnataka, Kerala, Maharashtra, Telangana, and Andhra Pradesh.
→No explicit numeric order book or pending orders mentioned, but the company is actively exploring opportunities within existing clusters.
→Existing announced projects are expected to conclude commissioning by end of FY 2027.
→Post stabilization of current projects, new greenfield projects will be initiated, implying a steady inflow of future orders.
→Incremental bed additions are ongoing across several locations, such as Ongole, Anantapur, Kondapur, and Rajamundry, with phased commissioning continuing.

Capex plans

Yes

→The company is currently commissioning new hospital beds in multiple locations including Thane, Bangalore, Nashik, and Maharashtra cluster, with phased bed additions planned (e.g., starting with 50-100 beds, gradually increasing to full capacity over 3-4 years).
→Significant greenfield and brownfield expansions are ongoing, particularly in Telangana, Andhra Pradesh, Karnataka, Kerala, and Maharashtra.
→New facilities in Bangalore (800 beds) and Thane (300 beds) are being brought online, with anticipated EBITDA breakeven within 12 months of operation.
→Expansion includes adding specialties such as oncology, pulmonology, cancer care, and mother and child care in Sunshine hospital and other locations.
→Focus is on stabilizing current expansions before initiating new greenfield projects—future expansions will continue around core clusters after FY'27 stabilization.
→Investment in digital health platforms, AI, and technology for improved patient care is ongoing to enhance scalability and quality.
→The company targets a steady-state ROCE of 20%-25% on ramped-up clusters.

How does Krishna Institute of Medical Sciences Ltd rank vs peers in Healthcare Services?

Pro feature

1Krishna Institute of Medical Sciences Ltd

Rev 2Mar 3

See full Healthcare Services sector rankings